파인메딕스
Financials
Valuation Metrics
파인메딕스's Market Cap is ₩350B. At end of 2025 it was ₩422B. Ranked #1982 of 2,421 in KR market (top 82%), #1251 of 1,640 on KOSDAQ (top 76%), #83 of 96 in Health Care Equipment & Services (top 86%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 34.99B KRW | KR#1,982/2,421 Sec#83/96 |
| Revenue | 11.43B KRW | KR#2,272/2,421 Sec#80/96 |
| Net Income | -599.4M KRW | KR—/2,421 Sec—/96 |
| Total Assets | 24.15B KRW | KR#2,365/2,421 Sec#93/96 |
| Net Assets | 19.13B KRW | KR#2,299/2,421 Sec#89/96 |
| Employees | 74 | KR#1,849/2,421 Sec#73/96 |
| Value | ||
| P/B | 1.83x | KR#1,884/2,421 Sec#63/96 |
| P/S | 3.06x | KR#1,989/2,421 Sec#65/96 |
| FCF Yield | -9.96% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | -3.13% | KR#1,724/2,421 Sec#59/96 |
| ROA | -2.48% | KR#1,793/2,421 Sec#61/96 |
| Op. Margin | -10.21% | KR#1,990/2,421 Sec#63/96 |
| Revenue Growth | -4.39% | KR#1,743/2,421 Sec#77/96 |
| Financial Health | ||
| Debt Ratio | 26.24% | KR#504/2,421 Sec#27/96 |
| Total Debt | 1.93B KRW | KR#1,916/2,421 Sec#73/96 |
| FCF | -3.49B KRW | KR#1,420/2,421 Sec#49/96 |
| Cash | 4.07B KRW | KR#2,079/2,421 Sec#81/96 |
| Current Ratio | 10.83x | KR#87/2,421 Sec#11/96 |
| Performance | ||
| 1Y Return | -24.42% | KR#1,389/2,421 Sec#32/96 |
| 1M Return | 3.67% | KR#869/2,421 Sec#24/96 |
| From 52W High | -34.73% | KR#691/2,421 Sec#21/96 |
| 1Y MDD | -57.61% | KR#1,343/2,421 Sec#44/96 |
| Trading | ||
| Volume | 6,717 shares | KR#2,047/2,421 Sec#83/96 |
| Trading Value | 41.1M KRW | KR#1,907/2,421 Sec#76/96 |
| Foreign Own. | 1.17% | KR#1,958/2,421 Sec#72/96 |
| Per Share | ||
| EPS | -107 KRW | KR—/2,421 Sec—/96 |
| BPS | 3,400 KRW | KR#1,772/2,421 Sec#49/96 |
Company Info
Fine Medic, established in 2009, is a specialized manufacturer of advanced digestive endoscopic procedure instruments, listed on KOSDAQ in 2024. The company has localized endoscopic incision knives, snares, and injectors, securing over 20% domestic market share and expanding sales in Japan, Europe, and the U.S. based on CE and FDA certifications. Leveraging the CEO's more than 20 years of clinical experience, Fine Medic has established a unified development system to promptly productize the needs of the medical field. It is headquartered in Dong-gu, Daegu Metropolitan City.